Andy is a Managing Partner of Section 32, a venture capital fund investing at the frontiers of technology, healthcare and life sciences.
He comes to Section 32 from leadership roles at Verily Life Sciences (previously Google Life Sciences) and X (previously GoogleX). At Verily, Andy was the Global Head of Business and Corporate Development and a member of the executive leadership team. Andy’s team executed global go-to-market campaigns for a wide range of next-generation healthcare technologies building creative and pioneering partnerships, collaborations and joint ventures in the US, Europe and Asia with some of the world’s top companies. Andy’s efforts directly contributed to Verily’s rapid scale, multi-billion dollar financing rounds and efforts to address the opioid and Covid-19 epidemics.
Andy co-founded and set up the Verily Ventures program to make early stage investments at the nexus of advanced technologies and healthcare. Under his stewardship, the program generated top tier venture returns in investments including Cortexyme (CRTX), Oscar (OSCR), Culture Robotics, Freenome, Syllable, Ciitizen, Mammoth Biosciences and others.
At GoogleX, Andy worked with a variety of projects across automation, quantum computing, life sciences, machine learning, artificial intelligence and other technology disciplines. He continues to advise X teams.
Prior to Google, Andy helped build and scale two businesses. One, a firm seeded by Stanford University’s Endowment which was successfully acquired and another, a health-care oriented private equity and credit firm active in San Francisco. He started his career at RBC Ventures at a fund which was a part of the DFJ Global Network.
Andy is a patented inventor with an Undergraduate Degree in Biochemical Engineering from McGill University and a Master in Biomedical Engineering from Cornell University. He also holds the Chartered Financial Analyst designation.